Payment overview · 2025
General Payments
$1,055.19
64 reported records · 17 companies
Healthcare provider profile · identity verified
Scott L. Boyens, MD
Allopathic & Osteopathic Physicians|Family Medicine · SIOUX FALLS, SD · NPI 1700886389
Verified facts
What the public records show
CMS Open Payments records show Scott L. Boyens, MD received $1,055.19 in general payments during 2025 across 64 reported records.
ABBVIE INC. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $256.23 | 24.3% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $178.17 | 16.9% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.50 | 8.7% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $76.73 | 7.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.94 | 5.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.09 | 4.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $49.99 | 4.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.90 | 4.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.66 | 4.6% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $39.27 | 3.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.81 | 3.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.96 | 3.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.54 | 3.1% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $16.96 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.34 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.46 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.64 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,055.19 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $164.35 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $164.35 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $97.44 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $76.73 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.46 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.88 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.22 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.94 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.06 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.06 | 9 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $49.99 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.90 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.66 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $39.27 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.54 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $27.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.67 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.67 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.67 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 432 | 112 |
| Omeprazole | Omeprazole | 426 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 67 |
| Gabapentin | Gabapentin | 290 | 49 |
| Losartan Potassium | Losartan Potassium | 284 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 63 |
| Lisinopril | Lisinopril | 238 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 224 | 49 |
| Simvastatin | Simvastatin | 218 | 54 |
| Meloxicam | Meloxicam | 215 | 55 |
| Metformin Hcl | Metformin Hcl | 179 | 32 |
| Tramadol Hcl | Tramadol Hcl | 174 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 36 |
| Metformin Hcl Er | Metformin Hcl | 146 | 33 |
| Sertraline Hcl | Sertraline Hcl | 131 | 22 |
| Furosemide | Furosemide | 123 | 30 |
| Allopurinol | Allopurinol | 122 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 20 |
| Potassium Chloride | Potassium Chloride | 104 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 25 |
| Lorazepam | Lorazepam | 90 | 18 |
| Alprazolam | Alprazolam | 88 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 16 |
| Donepezil Hcl | Donepezil Hcl | 80 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 15 |
| Olanzapine | Olanzapine | 74 | suppressed |
| Pregabalin | Pregabalin | 70 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 19 |
| Lactulose | Lactulose | 66 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Baclofen | Baclofen | 65 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 55 | suppressed |
| Methylprednisolone | Methylprednisolone | 54 | 52 |
| Eliquis | Apixaban | 53 | suppressed |
| Finasteride | Finasteride | 53 | 14 |
| Bupropion Xl | Bupropion Hcl | 51 | 17 |
| Mirtazapine | Mirtazapine | 51 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Xarelto | Rivaroxaban | 48 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 20 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Risperidone | Risperidone | 43 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 36 |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Ozempic | Semaglutide | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 40 | suppressed |
| Atenolol | Atenolol | 38 | 11 |
| Cephalexin | Cephalexin | 36 | 29 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Temazepam | Temazepam | 35 | 11 |
| Clonazepam | Clonazepam | 34 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Cefdinir | Cefdinir | 33 | 27 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Prednisone | Prednisone | 31 | 19 |
| Synthroid | Levothyroxine Sodium | 31 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Jantoven | Warfarin Sodium | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 23 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Estradiol | Estradiol | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Testosterone | Testosterone | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 13 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,055.19 · 64 records | ABBVIE INC. | ABRYSVO, Arikayce, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Heplisav-B, JARDIANCE, Kerendia, LEQVIO, LINZESS, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, YUPELRI, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error